about
Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscopePhase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.Association between mobilization regimen and PFS after auto-SCT for multiple myeloma.Enhanced responses to tumor immunization following total body irradiation are time-dependentNivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyA Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaAgonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunityDNA vaccines against cancer.OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.Combination immune therapies to enhance anti-tumor responses by NK cells.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study.DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation.Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma.Immune rejection of mouse tumors expressing mutated self.Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees.Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association.NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids.HIV-1 DNA vaccines and chemokines.Classifying ultra-high risk smoldering myeloma.Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple MyelomaAntibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studyAnti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaPrior exposure to superantigen can inhibit or exacerbate autoimmune encephalomyelitis: T-cell repertoire engaged by the autoantigen determines clinical outcomeGemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive diseaseModulating the immune response to genetic immunizationEnhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trialPredictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
P50
Q27334728-2F89789D-4BFE-469E-A77F-0C0A337694B9Q33432958-9E535976-5977-4411-9A87-B3CC0FE23B55Q33573450-905BBBDE-01E5-436C-BA8F-4B70C7FBBDFDQ33889676-E888BA63-6E15-4D97-88B5-FF4F11B21DA3Q35070312-09E7E674-C677-4CC2-98F9-9BA7A149D42DQ36043066-430A77D9-57A9-4AF9-AE81-DE04FD5E6FBEQ36070261-575A40D6-23DF-48E8-9045-248653715E26Q36274834-0B1D0232-D9BC-441A-829A-831EFA637A63Q36284584-D429A452-D6FB-4909-A6E0-736A48742506Q36459336-2F0C6EC4-896C-453D-84D8-BD01105AD1C9Q36500813-F119E842-5758-4950-9850-05469B95DFDCQ37273138-8FB48114-F92A-46D9-96AC-F3E41969E2BAQ37408550-DE2F8C8A-DFA6-4FDA-AD05-E06CC82BC76AQ38370539-F5CAED70-2C71-4A17-81EE-94EEA064729AQ40183492-5923F8F1-DD3B-48DA-9BA0-BD8C9AF5D8BAQ40190639-35502BC5-E05B-4AE7-AE82-7B8BF9E95F40Q40236095-C1CA9BC0-4922-47F8-ADCA-C3B4F0373F13Q41124362-6E0541FD-6285-48A0-8FD6-57D4573B7E59Q42145055-5EACFEE4-07B0-43FE-8808-154C9BBEF58BQ45747355-D8CDA27B-0A2D-4E66-A55E-EC9C28EF3D92Q46980729-1DD47A68-79F2-49D2-AC59-98F1A15729F5Q47236245-5D75419D-0322-47D4-ABCF-5A25DA2AC171Q47940964-A84B600B-0575-40E1-A7E3-756FBBA2D77EQ48972581-FBCA7555-AA47-4195-A504-F82FE0DAF22BQ50502690-59D43815-B39F-4854-9ACE-C2F8AC0FD1DFQ52579654-785620C6-16BB-4D95-B378-9D4A79D49A80Q52844166-5A6DAD55-0871-4F6E-80DA-088EC1F6C66DQ52844554-CC990860-BE2F-4BC9-B0E2-C96191B71013Q53006361-C29D8AF3-A09C-41FA-99F3-634932BE7244Q53148481-04BF91A0-E467-4CC1-88CD-FE58F70137B0Q53470095-2058AD3F-3807-4363-9105-34421BE15218Q55409204-532E48B6-C0F2-4943-8E8D-39F0DDD10EEBQ59136966-7AA5CDF9-F039-4ECB-B30F-2FFED4BA4894Q64068732-B11C1352-45E7-404E-A483-1397D4E646A3Q64120245-E77604FF-AB6C-4DE6-8A8D-DC60F96C26CEQ71941586-A58B4EAB-9E89-4276-A66F-D6CF65FFFD85Q74428168-C2F65D90-DDEC-494E-A3A2-183967D7C39EQ77630763-DB80AE23-4423-4B0B-908D-FA380368AC55Q77781802-59BD5C38-413E-4544-8BDC-F6A3F09BE934Q81762674-43E45717-069E-4B01-84E3-7C46CF751793
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Adam D Cohen
@ast
Adam D Cohen
@en
Adam D Cohen
@es
Adam D Cohen
@nl
type
label
Adam D Cohen
@ast
Adam D Cohen
@en
Adam D Cohen
@es
Adam D Cohen
@nl
prefLabel
Adam D Cohen
@ast
Adam D Cohen
@en
Adam D Cohen
@es
Adam D Cohen
@nl
P106
P21
P31
P496
0000-0003-0939-3843